ORIGINAL ARTICLE |
|
Year : 2021 | Volume
: 34
| Issue : 3 | Page : 909-913 |
|
Interleukin-6 levels in the serum and saliva in patients with oral lichen planus
Mohamed A Basha1, Shaymaa A. E Abd Elatef1, Eman M. Abd El Gayed2
1 Department of Dermatology, Andrology and STDs, Faculty of Medicine, Menoufia University, Menoufia, Egypt 2 Department of Medical Biochemistry, Faculty of Medicine, Menoufia University, Menoufia, Egypt
Correspondence Address:
Shaymaa A. E Abd Elatef Al Delengat, Al Beheira 22762 Egypt
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/mmj.mmj_64_20
|
|
Background
Oral lichen planus (OLP) is a chronic inflammatory and autoimmune disease that affects ~1.9–4% of the population. It occurs more frequently in women, and the immunological system is believed to play a significant role in it. Interleukin-6 (IL-6) is a cytokine that contributes to the pathogenesis of OLP.
Objectives
The objective of the study is to evaluate IL-6 levels in the serum and saliva in patients of OLP compared with healthy controls, aiming to help in the future treatments of OLP.
Patients and methods
This case–control study was conducted on 20 patients with OLP, and 20 age-matched and sex-matched healthy volunteers, as a control group.
Results
The results have shown that there was highly statistically significant difference between groups regarding serum IL-6 levels with higher levels among cases (P < 0.001).
Conclusion
Higher levels of IL-6 in the saliva compared with the serum suggest that measurement of this marker in the saliva may be more useful than the serum for diagnostic and therapeutic aims.
|
|
|
|
[FULL TEXT] [PDF]* |
|
|
|